Navigation Links
Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
Date:6/11/2008

Lead Candidate Set for Phase II Clinicals

LA JOLLA, Calif., June 11 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska" or the "Company"), announced today that it has been granted an exclusive, worldwide license from Duke University and Johns Hopkins University to develop and commercialize their rights to a portfolio of investigational cardiovascular drugs for the treatment of heart failure. The most advanced drug in the portfolio is expected to enter a Phase II clinical study later this year.

The drug portfolio was developed in part by Jonathan S. Stamler, M.D., George Barth Geller Professor of Research in Cardiovascular Diseases and Professor of Medicine and Biochemistry at Duke University, and Joshua M. Hare, M.D., Louis Lemberg Professor of Medicine, Chief of the Division of Cardiology and Director of the Interdisciplinary Stem Cell Institute at University of Miami. Dr. Hare was formerly associated with Johns Hopkins University.

The Phase II candidate and all other drugs in the portfolio are designed to correct nitric oxide and redox disequilibrium in the failing heart and cardiovascular system. All have a dual mechanism of action of inhibiting the creation of reactive oxygen radicals and concurrently providing nitric oxide in the failing heart. The therapeutic target is the ryanodine receptor, the ion channel in the heart that provides the calcium necessary for the heart to beat. The investigational drugs are believed to improve calcium cycling in the heart by acting on the ryanodine receptor to significantly improve the efficiency of heart contractility.

According to the National Heart, Lung and Blood Institute (NHLBI), there are an estimated five million Americans that suffer from congestive heart failure, a condition characterized by the inability of the heart to efficiently pump blood and by fluid accumulation in the lungs and other tissues. An estimated 300,000 deaths each y
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
2. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
3. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
4. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
5. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
8. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
9. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
10. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
11. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und LONDON ... , Ziel der Zusammenarbeit sind ... genomischer Daten aus Plasmaproben zur Steuerung von Therapien ... werden kann  Neuer Bluttest basiert auf ... und soll auf Rotor-Gene Q, einer Automationsplattform der ...
(Date:7/28/2014)... 2014 OmPrompt today announces ... help it meet the global demand for customer ... logistics. Albion joins Shackleton Ventures.      ... the past 18 months OmPrompt has underpinned accelerated ... team and its operations. The new funding will ...
(Date:7/25/2014)... N.C. , July 25, 2014  In today,s ... is costly and challenging - as is managing a ... Is it possible - or even preferable ... If so, where can you combine resources and activities, ... These are just a few of ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7OmPrompt Funded for Customer Automation Management Market Expansion 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... April 11, 2011 iCyt Mission Technology, Inc. (iCyt), ... announced the introduction of its new line of 405nm-excited ... Violet™ 421 products are part of the first commercial ... "This exciting new class of fluorescent probes will ...
... 11, 2011 Leading-edge Clinical Pharmacology and Cardiac ... announces the addition of Aziz Karim, BPharm, PhD, ... and advisor to Spaulding,s Clinical Pharmacology/Pharmacokinetic department.   ... the principles of Clinical Pharmacology and rational drug ...
Cached Medicine Technology:iCyt Unveils Exciting New Flow Cytometry Reagents Utilizing Innovative Fluorochrome Technology 2Spaulding Clinical Welcomes Dr. Aziz Karim, Clinical Pharmacokinetic Consultant 2
(Date:7/28/2014)... Amy Norton HealthDay ... Tonsillectomies are commonly done to relieve sleep apnea in children, ... kids, weight gain -- especially if they,re already overweight. ... risk factor for a range of health problems -- including, ... kids who need it. Instead, they said, doctors and ...
(Date:7/28/2014)... Lourdes Health System has partnered with ... wait times for veterans needing medical care. , Lourdes ... state—and the only one in Camden, Burlington and Gloucester ... program (PC3). PC3 gives veterans access to specialty care ... services due to lack of available specialists, long wait ...
(Date:7/28/2014)... 2014 The American Society ... professionals engaged in the field of organ transplantation, ... and Immunology Research Network (TIRN), a professional ... As modern organ transplantation continues to diversify, AST ... provide more opportunities for physicians, scientists and researchers ...
(Date:7/28/2014)... July 28, 2014 With California in ... is welcome news that a fire blanket ... protection is under development by SunSeeker Enterprises, Inc. The ... protect spacecraft from the extreme heat of re-entry into ... firefighters and homes. , “Our firefighters routinely lay their ...
(Date:7/28/2014)... Boston University School of Medicine (BUSM) report variants in ... of developing Alzheimer,s disease (AD). The discovery of this ... options that target PLXNA4 specifically. These findings appear in ... the most frequent age-related dementia affecting 5.4 million Americans ... and more than 40 percent of people age 85 ...
Breaking Medicine News(10 mins):Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3Health News:Lourdes Expands Military Partnership with Veterans 2Health News:Lourdes Expands Military Partnership with Veterans 3Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Researchers identify potential biomarker for AD 2
... throat strictures, cancer, group warns , FRIDAY, Aug. 31 ... heartburn once a month and more than 15 million ... of Gastroenterology. , Heartburn occurs when stomach contents ... tube that connects the mouth and the stomach. , ...
... to Help Ensure Success, ANAHEIM, Calif., Aug. 31 ... coach Tim Borland,will run a full marathon each day ... to a deadly children,s disease. His "A-T CureTour" -- ... take him,across the country, ending on Nov. 4 with ...
... MTD ) today announced the webcast of its,presentation ... on Friday, September 7, 2007, at 9:10 a.m. Eastern ... the investor relations page on the,Company,s Web site at ... be,available for seven days. METTLER TOLEDO is a ...
... Kan., Aug. 31 Juergen Richt, lead,scientist with ... and an adjunct professor at Iowa State University, ... Distinguished Professor. Richt,s appointment begins in April ... the College of Veterinary,Medicine, is the most prestigious ...
... Inc. (Nasdaq: AMCS ),a leader in radiology and medical image ... investors at the,Thomas Weisel Partners Healthcare Conference 2007 being held in ... -- Thursday, September 6, 2007 ... at 8:35 a.m. (Eastern Time), ...
... shows blocking 2 proteins could mean less invasive treatment ... -- The swelling that normally occurs when a joint ... researchers say. , Publishing in the September issue of ... two immune system proteins -- interleuken-1 and tumor necrosis ...
Cached Medicine News:Health News:Heartburn Can Be a Sign of Serious Disease 2Health News:Ultra-Runner to Run 63 Marathons in 63 Days for Children with Incurable Disease 2Health News:Ultra-Runner to Run 63 Marathons in 63 Days for Children with Incurable Disease 3Health News:Ultra-Runner to Run 63 Marathons in 63 Days for Children with Incurable Disease 4Health News:Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor 2Health News:Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor 3Health News:AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007 2Health News:Swelling After Knee Injury May Hinder Healing 2
... Pectoralis Implants come in three styles. ... is by far the most popular style. ... and are packaged and sold individually, not ... that they are each made for a ...
... In vivo results may be affected by the ... scar tissue can impact the desired augment-ation 1 ... from patient to patient. Implant dimensions can be ... surgical scissors. All dimensions in centimeters. This device ...
... in the IQmark family elevates your ECG and ... portability, cost-savings and efficient patient care. The IQmark ... the office, clinics and medical centers as well ... used in conjunction with the IQmark Digital ECG ...
24-hour full disclosure , Input range: 5mV , Analog bandwidth: 0.05 to 100Hz (3dB) , Common mode rejection ratio: 60dB , Dimensions: 4.46in. x 2.75in. x 1.02in. (113mm x 70mm x 26mm) , We...
Medicine Products: